Vyant Bio Inc

NASDAQ:VYNT   2:17:11 PM EDT
1.29
-0.03 (-2.27%)
Divestitures / Spin-offs, Earnings Announcements

Vyant Bio Reports Q3 Results And Provides Strategic And Business Highlights

Published: 11/15/2022 13:44 GMT
Vyant Bio Inc (VYNT) - Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights.
Vyant Bio Inc - $9.4 Million of Cash and Equivalents As of September 30, 2022.
Vyant Bio Inc - Current Cash Balances, Net Proceeds From Sale of Vivopharm Expected to Fund Operations Until at Least End of 2023.
Vyant Bio Inc - Future Proceeds From Equity Line of Credit and Atm Are Expected to Fund Operations Until at Least End of 2023.
Vyant Bio Inc - Qtrly Loss per Share $0.59.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.66

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.85

More details on our Analysts Page.